| Identification | Back Directory | [Name]
PKCε Inhibitor Peptide | [CAS]
182683-50-7 | [Synonyms]
epsilonV1-2
KNTBAGOTDJPUJV-XMTFRXHISA-N
L-α-Glutamyl-L-alanyl-L-valyl-L-seryl-L-leucyl-L-lysyl-L-prolyl-L-threonine | [Molecular Formula]
C37H63N9O12R2 | [MOL File]
182683-50-7.mol | [Molecular Weight]
825.949 |
| Chemical Properties | Back Directory | [Boiling point ]
1280.1±65.0 °C(Predicted) | [density ]
1.288±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 10 mg/ml; PBS (pH 7.2): 5 mg/ml | [form ]
A crystalline solid | [pka]
3.28±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
L-α-Glutamyl-L-alanyl-L-valyl-L-seryl-L-leucyl-L-lysyl-L-prolyl-L-threonine selectively and reversibly inhibits the translocation of PKC? to intracellular membranes, blocking activation. It is a calcium-independent, phospholipid- and diacylglycerol-dependent serine/threonine kinase. | [in vivo]
Epsilon-V1-2 (20 mg/kg/day; osmotic pumps; daily; for 4 weeks) treatment significantly improves the beating score in a murine heterotopic transplantation model. Epsilon-V1-2 reduces infiltration of macrophages and T cells into the cardiac grafts, and decreases parenchymal fibrosis. Epsilon-V1-2 treatment almost abolishes the rise in pro-fibrotic cytokine, TGF-β and monocyte recruiting chemokine MCP-1 levels[3]. | Animal Model: | C57BL/6J mice transplanted the hearts of FVB mice[3] | | Dosage: | 20 mg/kg/day | | Administration: | 0.1 mL osmotic pumps implanted subcutaneously; daily; for 4 weeks | | Result: | Significantly improved the beating score throughout the treatment.
|
| [IC 50]
PKCε | [storage]
Store at -20°C |
|
|